A Milestone for KRTL Holding Group, Inc. (OTC: KRTL)
KRTL Biotech, a subsidiary of KRTL Holding Group (OTC: KRTL), has achieved FDA registration, marking a strategic milestone in strengthening the U.S. pharmaceutical supply chain. The registration positions KRTL to facilitate international manufacturers' entry into the U.S. market, focusing on delivering high-quality active pharmaceutical ingredients (APIs) and finished products. The company plans to establish a manufacturing and distribution facility in 2025 to support both domestic and international partners. This initiative aims to provide lower-cost alternatives and optimized logistics solutions, enhancing supply chain stability while generating cost savings for the healthcare sector.
KRTL Biotech, una sussidiaria del KRTL Holding Group (OTC: KRTL), ha ottenuto la registrazione dalla FDA, segnando un traguardo strategico nel rafforzare la catena di approvvigionamento farmaceutico negli Stati Uniti. La registrazione posiziona KRTL per facilitare l'ingresso dei produttori internazionali nel mercato statunitense, con focus sulla fornitura di ingredienti farmaceutici attivi (API) e prodotti finiti di alta qualità. L'azienda prevede di stabilire un impianto di produzione e distribuzione nel 2025 per supportare sia i partner nazionali che internazionali. Questa iniziativa mira a fornire alternative a costi inferiori e soluzioni logistiche ottimizzate, migliorando la stabilità della catena di approvvigionamento e generando risparmi per il settore sanitario.
KRTL Biotech, una subsidiaria de KRTL Holding Group (OTC: KRTL), ha logrado la inscripción de la FDA, marcando un hito estratégico en el fortalecimiento de la cadena de suministro farmacéutico en EE. UU. La inscripción posiciona a KRTL para facilitar la entrada de fabricantes internacionales en el mercado estadounidense, centrándose en ofrecer ingredientes farmacéuticos activos (API) y productos terminados de alta calidad. La empresa planea establecer una instalación de fabricación y distribución en 2025 para apoyar tanto a socios nacionales como internacionales. Esta iniciativa busca proporcionar alternativas de menor costo y soluciones logísticas optimizadas, mejorando la estabilidad de la cadena de suministro y generando ahorros para el sector salud.
KRTL Biotech는 KRTL Holding Group (OTC: KRTL)의 자회사로, FDA 등록을 완료하여 미국 제약 공급망 강화를 위한 전략적 이정표를 세웠습니다. 이번 등록은 KRTL이 국제 제조업체의 미국 시장 진입을 촉진할 수 있는 기회를 제공하며, 고품질의 활성 제약 성분(API)과 완제품을 제공하는 데 중점을 두고 있습니다. 이 회사는 2025년에 국내 및 국제 파트너를 지원하기 위한 제조 및 유통 시설을 설립할 계획입니다. 이 주 initiative는 비용 절감과 최적화된 물류 솔루션을 제공하여 공급망 안정성을 높이고 의료 부문에 비용 절감을 가져오는 것을 목표로 하고 있습니다.
KRTL Biotech, une filiale de KRTL Holding Group (OTC: KRTL), a obtenu l'enregistrement de la FDA, marquant une étape stratégique dans le renforcement de la chaîne d'approvisionnement pharmaceutique aux États-Unis. Cet enregistrement positionne KRTL pour faciliter l'entrée des fabricants internationaux sur le marché américain, en se concentrant sur la fourniture d'ingrédients pharmaceutiques actifs (API) et de produits finis de haute qualité. L'entreprise prévoit d'établir une installation de fabrication et de distribution en 2025 pour soutenir des partenaires nationaux et internationaux. Cette initiative vise à offrir des alternatives à moindre coût et des solutions logistiques optimisées, améliorant ainsi la stabilité de la chaîne d'approvisionnement tout en générant des économies pour le secteur de la santé.
KRTL Biotech, eine Tochtergesellschaft der KRTL Holding Group (OTC: KRTL), hat die FDA-Zulassung erreicht, was einen strategischen Meilenstein zur Stärkung der US-amerikanischen pharmazeutischen Lieferkette darstellt. Die Zulassung positioniert KRTL, um internationalen Herstellern den Eintritt in den US-Markt zu erleichtern, wobei der Fokus auf der Bereitstellung hochwertiger aktiver pharmazeutischer Wirkstoffe (APIs) und Fertigprodukte liegt. Das Unternehmen plant, 2025 eine Produktions- und Vertriebsanlage einzurichten, um sowohl nationale als auch internationale Partner zu unterstützen. Diese Initiative zielt darauf ab, kostengünstigere Alternativen und optimierte Logistiklösungen zu bieten, die die Stabilität der Lieferkette verbessern und Einsparungen im Gesundheitssektor generieren.
- FDA registration achievement enables market expansion and new partnership opportunities
- Planned establishment of manufacturing and distribution facility in 2025
- Strategic positioning to facilitate international manufacturers' entry into U.S. market
- None.
KRTL Biotech Achieves FDA Registration, Advancing Global Pharmaceutical Access and U.S. Supply Chain Resilience
Lakewood, CO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- KRTL Holding Group, Inc. (OTC: KRTL) announces a major strategic milestone: its subsidiary, KRTL Biotech Inc., has successfully completed the registration process with the U.S. Food and Drug Administration (FDA). This achievement is central to KRTL’s mission of fortifying the U.S. pharmaceutical supply chain by facilitating the seamless integration of international manufacturers, ultimately benefiting the healthcare ecosystem at both a national and global level.
The FDA registration of KRTL Biotech is not merely a regulatory checkpoint but a foundational advancement towards enhancing the resilience and diversification of the pharmaceutical supply chain. By adhering to the rigorous standards set forth by the FDA, KRTL Biotech is positioned to support international pharmaceutical manufacturers in delivering high-quality active pharmaceutical ingredients (APIs), novel compounds, and finished products to the U.S. market upon future establishment of dedicated manufacturing facilities. This strategic initiative is designed to provide lower-cost alternatives and optimized logistics solutions, thereby strengthening supply chain stability while generating significant cost savings for the healthcare sector.
Strategic Benefits for the U.S. Market
- Enhanced Supply Chain Resilience: By enabling international manufacturers to enter the U.S. market, KRTL Biotech aims to foster a more diversified and resilient pharmaceutical supply chain, bolstering adaptability and reliability in addressing healthcare demands.
- Cost-Efficiency for the Healthcare System: Through the provision of APIs and finished products at reduced costs, KRTL Biotech’s initiatives are designed to alleviate the financial strain on the U.S. healthcare system, thereby enhancing access to essential medications for patients.
- Quality Assurance and Innovation: KRTL Biotech's commitment to compliance and quality facilitates international partners in achieving U.S. regulatory standards, thereby establishing new benchmarks for innovation and quality in pharmaceutical manufacturing.
A Strategic Move for Global Impact
This milestone is a transformative step that goes beyond corporate growth; it positions KRTL Biotech as a catalyst for meaningful change in the pharmaceutical landscape, both domestically and internationally. By providing a pathway for international manufacturers, KRTL Biotech aims to support the United States in maintaining its leadership in pharmaceutical innovation and
Shareholder Benefits and Future Plans
KRTL Holding Group's shareholders are positioned to benefit significantly from the FDA registration through enhanced partnership opportunities, an expanded market presence, and a strengthened position within the pharmaceutical sector. By facilitating the entry of international manufacturers into the U.S. market, KRTL Biotech aims to generate value not only for shareholders but also for the broader U.S. healthcare market, contributing to a more competitive supply chain with cost-effective, high-quality products.
Looking forward, KRTL is committed to expanding its influence further by establishing a cutting-edge manufacturing and distribution facility in financial year 2025. This facility will serve as a cornerstone of KRTL’s strategy to augment production capacity, optimize distribution logistics, and provide comprehensive support to both domestic and international partners. This endeavor will solidify our commitment to ensuring that the U.S. healthcare system has reliable access to affordable, high-quality pharmaceutical products, thereby reinforcing our contribution to the public health infrastructure.
CEO’s Statement
“Securing FDA registration represents a pivotal moment for KRTL Biotech, one that enables us to make a substantial contribution to the global pharmaceutical ecosystem,” said Cesar Herrera, CEO of KRTL Holding Group, Inc. “Our strategic goal is to reinforce the U.S. supply chain by integrating high-quality, cost-effective products from international manufacturers. This ensures that we are well-positioned to meet the evolving healthcare needs of our population. This achievement is not simply about regulatory compliance—it is about empowering our partners and enhancing patient care standards worldwide.”
About KRTL Holding Group, Inc.
We are interested in having a competitive edge in the marketplace, through mergers & acquisitions, collaborations, and strategic alliances with specific partners.
KRTL Holding Group Inc., a holding company which operates through its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. These subsidiaries have evolved to focus on distinct industries, yet they intricately intertwine, forming the bedrock of the KRTL brand. This strategic synergy empowers KRTL Holding Group to actively pursue investment opportunities and forge invaluable partnerships, ultimately enhancing shareholder value.
Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
FAQ
What is the significance of KRTL Biotech's FDA registration for KRTL stock (OTC: KRTL)?
When will KRTL (OTC: KRTL) open its new manufacturing facility?
How will KRTL Biotech's FDA registration impact the U.S. pharmaceutical supply chain?
